Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Merrimack Pharmaceuticals has commenced the dosing of first patient in a Phase 1 clinical study, with MM-121 in combination with a standard treatment regimen, for treatment of advanced solid tumors.
Subscribe to our email newsletter
MM-121 is a fully human monoclonal antibody that targets ErbB3.
The trial is intended to assess the safety and pharmacokinetics of MM-121 when administered in combination with separate chemotherapy regimens.
The study sites in North America and the European Union are likely to participate in this trial.
Merrimack signed an exclusive, global collaboration and licensing agreement with Sanofi for MM-121 in 2009.